A review of studies including 20,000 patients with NMIBC highlights the need for individualized NMIBC management that balances oncologic control with QoL and patient-reported outcomes. Frequent ...

PARSIPPANY, N.J.--(BUSINESS WIRE)--Ferring Pharmaceuticals today announced the first patient in the United States with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder ...

Association between combination of VI-RADS based on T2WI and morphological features and pathological outcome and prognosis in bladder cancer. This is an ASCO Meeting Abstract from the 2025 ASCO ...

WASHINGTON -- The gene therapy nadofaragene firadenovec (Adstiladrin) continued to demonstrate clinical activity in patients with high-risk bladder cancer, researchers reported. The long-term ...

Researchers from Shenzhen University and affiliated organizations detailed the preclinical characterization of a synergistic intravesical instillation of fenbendazole (FBZ) and CRISPR-Cas13a-based ...

Therapeutic options to treat intermediate-risk and BCG-unresponsive bladder cancer, such as medications and ablative therapies, are expanding, and novel PET tracers enable improved diagnosis and ...

The FDA has signed off on Johnson & Johnson’s highly anticipated bladder cancer drug Inlexzo, marking an advance in the ability to care for patients who otherwise face bladder removal and limited ...

UGN-102 could become the first FDA-approved treatment for low-grade intermediate-risk non-muscle-invasive bladder cancer, with a PDUFA goal date of June 13, 2025. The phase 3 ENVISION trial ...

Relmada Therapeutics announced a licensing agreement for NDV-01, a new treatment for non-muscle invasive bladder cancer. Phase 2 data expected in April 2025. Relmada Therapeutics, Inc. has announced ...

Safety and efficacy evaluation of nadofaragene firadenovec instilled into the renal pelvis in subjects with low-grade upper tract urothelial carcinoma (LG-UTUC): A single-arm, open-label phase 1/2 ...